Rhumbline Advisers 23and Me Holding Co. Transaction History

Rhumbline Advisers

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$0.36 - $0.61 $128,043 - $216,961	-355,675 Reduced 85.12%	62,184 $24,000
Q1 2024 May 09, 2024	BUY	$0.4 - $0.91 $8,628 - $19,628	21,570 Added 5.44%	417,859 $221,000
Q4 2023 Feb 08, 2024	BUY	$0.71 - $0.97 $17,511 - $23,924	24,664 Added 6.64%	396,289 $360,000
Q3 2023 Nov 09, 2023	BUY	$0.96 - $2.01 $1,536 - $3,218	1,601 Added 0.43%	371,625 $364,000
Q2 2023 Aug 08, 2023	BUY	$1.59 - $2.29 $29,718 - $42,802	18,691 Added 5.32%	370,024 $647,000
Q1 2023 May 11, 2023	BUY	$2.05 - $2.87 $57,367 - $80,314	27,984 Added 8.65%	351,333 $801,000
Q4 2022 Feb 14, 2023	BUY	$2.06 - $3.47 $33,444 - $56,335	16,235 Added 5.29%	323,349 $698,000
Q3 2022 Nov 10, 2022	BUY	$2.6 - $5.12 $239,343 - $471,321	92,055 Added 42.8%	307,114 $878,000
Q2 2022 Aug 11, 2022	BUY	$2.19 - $3.98 $470,979 - $855,934	215,059 New	215,059 $533,000

116

82.6M

404K

292K

Ticker ME
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 259,768,000
Market Cap $992M
Description
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of pa...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.